Skip to main content

Investor Relations

Welcome to our dedicated page for investor resources. You will find everything you need if you want to invest in pioneering medical science.

Dedicated to solving some of today’s biggest public health challenges, bioMérieux has the focus and the capabilities to discover, develop, and commercialize advanced medical diagnostics solutions that have an impact on people’s lives. We combine the dynamism of a technology-fueled company with the long-term thinking of our founding family. It is this alliance that shapes our strategy and success.

A values-based company, we aim for strong and sustainable performance that benefits our shareholders, our employees, and society.


2022 Financial Results

  • Strong sales growth in the fourth quarter:
    • Organic growth of 5.9%
    • Very high demand for respiratory panels within the “tripledemic” (Flu/Covid/RSV) context
    • Remarkable growth in non-respiratory panels and Industrial Applications  
  • Strong performance in 2022 with robust full-year sales and 18.5% contributive operating margin, above initial expectations
    • Full-year sales at €3,589 million with a reported growth of +6.3% 
    • Almost neutral organic growth of +0.2%, thanks to a strong growth of BIOFIRE® non-respiratory panels, a solid growth of Microbiology and Industrial Applications, offsetting the slowdown in Immunoassays and stable sales for respiratory panels
    • Contributive operating income at €664 million, representing an operating margin of 18.5%, lower than exceptionally high level of 2021, but significantly higher than pre-pandemic margin levels Contributive operating income at €664 million representing an operating margin of 18.5%, lower than exceptionally high level of 2021, but significantly higher than pre-pandemic margin levels 
  • Confirmed 2023 guidance
    •  In 2023, excluding respiratory panels, sales growth is expected to reach +8% to +10% at constant exchange rates and scope of consolidation, driven by a solid growth of BIOFIRE® non-respiratory panels as well as Microbiology and Industrial applications. Assuming a slowdown for respiratory panels sales, total Group sales would be evolving within a +4% to +6% range on a like-for-like basis.
    • Contributive operating income before non-recurring items should be in a range of €600 million to €630 million, at forecasted exchange rates, including a €40 million estimated unfavorable foreign exchange impact. 

“In 2022, bioMérieux achieved a solid performance and adjusted upward its guidance during the year. The year has been marked by the acquisition of Specific Diagnostics which reinforces our product offering and our long-standing commitment to the fight against antimicrobial resistance. 2022 has been also an intense year in R&D and launch of several new platforms that will contribute to strengthen our market positions and sustain our growth”

Alexandre Mérieux, Chairman and CEO

URD/Annual Reports

See most comprehensive information about bioMérieux.


Discover our plans to a sustainable future.


Our boards and committees underpin our ability to make decisions and ensure control processes. 

News & publications

bioMérieux combines long-term growth and profitability. Learn more about our performance and activities in our detailed reports and financials.

Analysts coverage & consensus

Financial analysts keep track of our performance. Discover their forecasts here.

Shareholder Area

Already a bioMérieux shareholder or want to start investing?

Regulated Information

To guarantee transparency and sustainability, we abide by a strict set of rules and regulations.